已收盘 03-18 16:00:00 美东时间
0.000
0.00%
热门中概股走势分化!再鼎医药大涨超6%,抗精神分裂症新药国内获批上市;拼多多、贝壳涨超1%;霸王茶姬跌近3%,金山云、网易、哔哩哔哩跌超1%>>
2025-12-24 23:44
Karuna Therapeutics, Inc. (($KRTX)) announced an update on their ongoing clinic...
2025-08-16 00:24
(来源:动脉新医药) 当地时间2025年7月28日,中枢神经系统疾病治疗方法开发商MapLight Therapeutics宣布完成3.725亿美元的超额认购...
2025-07-30 16:42
Karuna Therapeutics, Inc. (($KRTX)) announced an update on their ongoing clinic...
2025-07-03 00:14
1月17日,再鼎医药宣布KarXT(呫诺美林+曲司氯铵)用于治疗成人精神分裂症的新药上市申请(NDA)已获国家药品监督管理局(NMPA)受理。 Kar...
2025-01-18 08:08
转自:中国医药报 9月26日,美国食品药品管理局(FDA)批准了百时美施贵宝公司的Cobenfy(Xanomeline and Trospium chlor...
2024-12-19 07:34
Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy, Cobenfy, improved disease symptoms with a well-tolerated safety profile over 12 months across two Phase 3 trials. In Sept...
2024-11-01 22:46
FDA周四批准了由美国医药巨头百时美施贵宝公司开发的Cobenfy(xanomeline以及trospium chloride),作为治疗精神分裂症成人患者的最新疗法。
2024-09-27 20:55
PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that KarXT
2024-09-27 14:39
2024年9月26日,百时美施贵宝(BMS)同类首创新药Cobenfy (xanomeline和trospium chloride复方,KarXT)顺利获得F...
2024-09-27 13:37